|
gptkbp:instance_of
|
gptkb:immunotherapy
|
|
gptkbp:administered_by
|
oral tablet
|
|
gptkbp:approves
|
gptkb:1997
gptkb:FDA
|
|
gptkbp:atccode
|
B01 AC04
|
|
gptkbp:available_on
|
generic medication
|
|
gptkbp:brand
|
gptkb:Plavix
|
|
gptkbp:casnumber
|
113665-84-2
|
|
gptkbp:chemical_formula
|
C16 H16 Cl N2 O2 S
|
|
gptkbp:clinical_trial
|
Phase IV
Phase III
|
|
gptkbp:clinical_use
|
stenting procedures
thrombosis prevention
secondary prevention of cardiovascular events
after stent placement
after heart surgery
|
|
gptkbp:contraindication
|
severe liver disease
active bleeding
|
|
gptkbp:dosage_form
|
75 mg daily
|
|
gptkbp:drug_interactions
|
gptkb:esomeprazole
gptkb:omeprazole
gptkb:warfarin
NSAIDs
|
|
gptkbp:excretion
|
urine
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
clopidogrel
|
|
gptkbp:lifespan
|
8 hours
|
|
gptkbp:loading_dose
|
300 mg
|
|
gptkbp:marketed_as
|
gptkb:Sanofi
gptkb:Bristol-Myers_Squibb
|
|
gptkbp:mechanism_of_action
|
inhibits platelet aggregation
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:related_products
|
gptkb:ticagrelor
abciximab
eptifibatide
prasugrel
|
|
gptkbp:safety
|
Category B
|
|
gptkbp:side_effect
|
bruising
diarrhea
bleeding
itching
|
|
gptkbp:suitable_for
|
pregnancy
breastfeeding
|
|
gptkbp:used_for
|
preventing blood clots
|
|
gptkbp:used_in
|
gptkb:Cardiology
ischemic stroke
percutaneous coronary intervention
acute coronary syndrome
|
|
gptkbp:bfsParent
|
gptkb:Prilosec_OTC
gptkb:Nexium
|
|
gptkbp:bfsLayer
|
5
|